Vor Biopharma (VOR) Stock Price, News & Analysis

Company Overview

Vor Biopharma Inc. is a clinical-stage biotechnology company focused on developing engineered hematopoietic stem cell and targeted immunotherapy treatments for cancer, particularly hematologic malignancies such as acute myeloid leukemia (AML). The company’s approach is designed to combine gene-edited blood stem cells with targeted therapies intended to improve the ability to treat disease while protecting healthy blood-forming cells.

Vor’s technology platform has included engineered hematopoietic stem cells designed to remove or alter specific cell-surface targets, along with targeted immunotherapies intended to eliminate malignant cells that retain those targets. Its development programs have included VOR33, an engineered stem cell therapy designed to lack the CD33 protein, and VCAR33, a CD33-directed CAR-T cell therapy. The company has evaluated these approaches as potential components of a treatment strategy for AML and other blood cancers.

Founded in 2015 and headquartered in Cambridge, Massachusetts, Vor Biopharma operates primarily as a research and clinical-development company serving the biopharmaceutical market. Its programs are in development and have not established products broadly available to patients. Vor Biopharma’s leadership has included Robert Ang, M.D., as chief executive officer.

Key Stats

• Today's Range: $17.86 to $18.90
• 50-Day Range: $18.06 to $25.10
• 52-Week Range: $6.50 to $34.63
• Volume: 563,085 shs
• Average Volume: 1.06 million shs
• Market Capitalization: $1.11 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $41.71
• Consensus Rating: Moderate Buy

Vor Biopharma Stock Analysis - MarketRank™

Vor Biopharma scored higher than 35% of companies evaluated by MarketBeat, and ranked 713th out of 884 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.9 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Vor Biopharma has received a consensus rating of Moderate Buy. The company's average rating score is 2.90, and is based on 2 strong buy ratings, 5 buy ratings, 3 hold ratings, and no sell ratings.

Upside Potential

Vor Biopharma has a consensus price target of $41.71, representing about 122.1% upside from its current price of $18.78.

Amount of Analyst Coverage

Vor Biopharma has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Vor Biopharma are expected to decrease in the coming year, from ($2.56) to ($3.43) per share.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

13.40% of the float of Vor Biopharma has been sold short.

Short Interest Ratio / Days to Cover

Vor Biopharma has a short interest ratio ("days to cover") of 11.12, which indicates bearish sentiment.

Change versus previous month

Short interest in Vor Biopharma has recently increased by 3.10%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Vor Biopharma does not currently pay a dividend.

Dividend Growth

Vor Biopharma does not have a long track record of dividend growth.

News and Social Media

• Score: 2.0 / 5
• News Sentiment: 0.22

News Sentiment

Vor Biopharma has a news sentiment score of 0.22. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.42 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Vor Biopharma this week, compared to 4 articles on an average week.

MarketBeat Follows

1 people have added Vor Biopharma to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.4 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Vor Biopharma insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $4,207.00 in company stock.

Percentage Held by Insiders

0.27% of the stock of Vor Biopharma is held by insiders.

Percentage Held by Institutions

97.29% of the stock of Vor Biopharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/11/2026
• Today: 10/07/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:VOR
• Previous Symbol: NASDAQ:VOR
• CIK: 1817229
• Web: vorbio.com
• Phone: (617) 655-6580
• Fax: N/A
• Employees: 76
• Year Founded: 2016

Price Target and Rating

• Average Price Target for Vor Biopharma: $41.71
• High Price Target: $64.00
• Low Price Target: $27.00
• Potential Upside/Downside: +122.1%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.90
• Research Coverage: 10 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 59,160,000
• Free Float: 59,002,000
• Market Cap: $1.11 billion
• Optionable: N/A
• Beta: 1.78